Rising Prevalence of Preterm Birth Fuelling the Market Growth

The increasing prevalence of premature births is greatly fuelling the need for more advanced testing and diagnostic options, resulting in the preterm births and PROM testing market growth. The heightened chance of infections and other issues for mothers and infants (including the use of baby monitor devices) highlights the necessity of efficient screening instruments. As per the 2023 WHO report, close to 1 million infants die each year because of complications related to preterm birth, which is a major factor in child mortality. More than 20% of deaths before age five are due to preterm births, frequently caused by infections during pregnancy, with the risk increasing as the baby is born earlier. The need for better diagnostic tools to manage and reduce the risks associated with preterm births and premature rupture of the membranes (PROM) is being fuelled by these alarming data. With advancements in screening and diagnostic technologies to improve early detection and outcomes for moms and babies, healthcare is progressing. This evolving scenario also strengthens the overall preterm births and PROM testing market analysis.

Furthermore, according to one of the reports, mothers with a PROM duration of over 72 hours showed a higher risk of placental infection, and babies are at higher risk for pneumonia and intracranial haemorrhage, resulting in an increasing need for Point-of-Care testing. Additionally, from the reports of NIH, women with preterm prelabour rupture of membranes showed a 7.3% statistically higher incidence in the HPV-positive group compared to the 3.2% HPV negative group; for this reason, many market players are conducting research to reduce per-test cost and enhance the accuracy of results, significantly benefiting the market growth.  For instance, in January 2024, the Ministry of Health British Columbia announced the launch of self-screening programs to detect cervical cancer, offering to choose and order a self-screening kit for the human papillomavirus to take prevention into their own hands. 

preterm births and PROM testing market analysis showing test type segmentation, diagnostic accuracy trends, and clinical adoption patterns

Growing Awareness for Customized Diagnostic Solutions is Driving Market Growth

Growing awareness and advancements in the efficiency, accuracy, and affordability of prenatal testing are driving market growth and encouraging the implementation of AI-powered screening programs. These innovations enhance prenatal care by providing more precise and timely diagnostics and introducing innovative products by market players. For instance, in December 2023, Siemens Healthineers announced the launch of the Acuson Maple AI-powered Ultrasound system, which has received FDA approval. This advanced system aims to address repetitive tasks and streamline radiology workflows. It features automatic calculations for fetal age and weight, reducing examination time by 24% compared to traditional ultrasound methods. Additionally, the system offers 75 minutes of unplugged scanning capability and includes 25 features designed to improve usability and workflow efficiency; such developments are improving the effectiveness and accessibility of prenatal care, which is greatly enhancing the management of maternal and newborn health, including improved feeding support tools like baby feeding bottle solutions. An important advancement in prenatal care is the incorporation of AI into screening tools, which could improve operational effectiveness and diagnostic accuracy, shaping a stronger preterm births and PROM testing market outlook.


Moreover, with rising demand for early detection and intervention to prevent preterm birth and PROM testing to determine the risk of early delivery and identify the signs of labor and assessment of risk factors, many market players are developing technological solutions to reduce health disparities and provide disease diagnosis and onset of preterm delivery-related information. For instance, in March 2024, EDEN collaborated with GH Labs to announce the launch of an AI-enabled ultrasound device to revolutionize healthcare access, particularly in low- and middle-income countries, to identify high-risk pregnancies, provide timely interventions, enhance prenatal care, support health organizations, and update clinical guidelines. 

Recent Trends in the Preterm births and PROM Testing Industry

  • AI and machine learning to analyze a complex data set
  • Improving imaging techniques for better visualization of the cervix and fetus
  • Wearable uterine tracking device enabling real-time monitoring
  • Advances in biomarker tests for more accurate predictions
  • Accessibility of an at-home testing kit allows for a preliminary test
  • Advances in genomics and availability of tailored interventions

These developments reflect ongoing preterm births and PROM testing market segmentation and evolving diagnostic adoption patterns, while also reinforcing key preterm births and PROM testing market trends across healthcare systems.

Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs...!
Uncover Scope

High Cost and Trained Professional Shortage Impacts the Market Growth

Complexity in operating advanced diagnostic tools, including biomarkers and imaging systems, can be expensive, and a lack of skilled operator is a major challenge limiting their accessibility in certain regions and healthcare settings. Specialized skilled trainers are needed to operate, with interdisciplinary knowledge, creating a barrier to widespread adoption. Access to training might be less in rural or remote areas in the healthcare sector, and these differences can impact the expansion of the market. In addition, management of large amounts of data requires effective analysis, which can be a challenge for healthcare facilities with limited resources, impacting preterm births and PROM testing industry analysis and overall market growth.

 

However, ensuring proper use and interpretation of new diagnostic tests related to new diagnostic technologies and testing solutions can be challenging when integrating with existing healthcare systems and electronic health records (EHRs). For instance, in December 2023, Actim announced the release of a field safety notice for the Actim Partus and PROM test due to testing result interference because of the presence of lubricants in the vaginal specimen, resulting in misleading clinical decision-making and causing a risk of under and overtreatment of the patient. This also influences the overall preterm births and PROM testing market share dynamics across regions.

Advancements in Inheritable Testing Technology Fuels the Market Growth

With increasing emphasis on screening to reduce the prevalence of cervical cancer cases, as clinical trials have shown an association between the excisional procedure for cervical cancer and the risk of preterm delivery, resulting in innovations in diagnostic technology by market players, such as improved biomarkers and advanced imaging techniques, to reduce the number of cases. For instance, in January 2024, Life Cell announced the launch of an at-home self-test kit for women to screen for Human Papillomavirus (HPV), providing home comfort. Additionally, in March 2024, Roche announced the launch of an HPV self-collection solution to improve testing access for women, providing private collection of own samples, helping in identifying early detection of developing cervical cancer in women and expanding the capabilities of preterm birth and PROM detection. This expansion is expected to significantly influence the preterm births and PROM testing market forecast, alongside contributing to a growing preterm births and PROM testing market size.

Furthermore, the growing advancements in testing for inheritable health conditions and the rise of e-commerce platforms are driving increased demand for advanced diagnostic options. This shift is prompting market players to introduce new testing solutions aimed at early diagnosis. For instance, in July 2023, Quest Diagnostics introduced a next-generation sequencing (NGS)-powered genetic test utilizing saliva specimens. This novel test is intended to determine the likelihood of developing nearly two dozen hereditary diseases, such as blood disorders associated with particular genes and cancers of the breast and colon.

The test is available through the company's online platform, Genetic Insights, which also provides personalized access to genetic counseling. This development reflects a broader trend towards integrating advanced genetic testing with accessible online services, enhancing early detection and personalized healthcare. As technology continues to evolve and e-commerce platforms expand, the availability and adoption of such advanced diagnostic tools are expected to grow, further supporting early diagnosis and informed health management. 

Searching for a Country or Region Specific Report?

Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost

Outline Geography

Increase in Maternal Age Expands the Market Growth

In North America, there is a notable increase in preterm births and the Point-of-Care (POC) testing market due to an increase in premature births, improved technology, and a robust healthcare system. Healthcare facilities in the area are putting more emphasis on enhancing results with advanced screening and intervention methods. The market for POC testing is strong due to continuous technological advancements and high usage in medical facilities. The U.S. and Canada are leading the way in implementing advanced POC tests that offer quick and precise results, essential for improving the management of preterm births. This increase shows North America's dedication to improving prenatal care and health outcomes for mothers and infants.

However, Latin America has preterm births, and the POC testing market is growing steadily due to differences in socioeconomic status and access to healthcare. With rising investments in healthcare technology and infrastructure, the POC testing market is expanding. Though gaps still exist, nations such as Brazil and Mexico are improving their ability to provide prenatal care. POC tests are becoming more widely available over time, which will aid in better early preterm birth detection and care.

Europe region is accounting for growth due to rising awareness campaigns and initiatives undertaken by non-profit organizations to address challenges faced by premature babies and their families, and increasing government funding for rapid technological advancements, resulting in market growth. Increasing funding from the government for technological advancements continues to drive the growth of the market. Countries such as Germany and the UK are at the forefront of adopting new technologies and improving prenatal care practices, contributing to a growing demand for effective POC testing solutions in enhancing the early identification and control of premature births, fuelling the expansion of the point-of-care testing sector in the area.

In addition, the Asia-Pacific market is significantly due to rising preterm birth rates, driven by factors such as increasing maternal age and healthcare disparities, as well as increasing healthcare expenditure and growing investment by leading companies, creating a potential market in these regions and rising awareness, improving healthcare infrastructure, and a burgeoning middle class. Countries such as China and India are seeing significant investments in POC technologies to address preterm birth challenges, improving both the accessibility and standard of prenatal care, while also backing the advancement and acceptance of innovative POC technologies. Due to this, the Asia-Pacific region is experiencing an increase in market activity and growth, showing its dedication to enhancing maternal and infant health outcomes with advanced diagnostic and testing solutions, alongside improved adoption of supportive newborn care infrastructure such as baby bassinets.

Furthermore, the Middle East and Africa region faces challenges associated with high rates of preterm births, which are caused by socioeconomic problems and barriers to healthcare. These issues are linked to elevated levels of premature deliveries. Although the Point-of-Care (POC) testing market is still in its infancy, it is showing promise given the growing emphasis on using technology to improve maternal health.

Geographic Coverage of the Report:
 

North America

United States, Canada
Latin America

Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America
Europe

Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe
Asia Pacific

China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific
Middle East and Africa

GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs...!
Uncover Scope

Global Preterm Births and PROM Testing Market Covers:

  • Mapping segmentation across diagnostic test type, assay technology, and end-user adoption in the preterm births and prom testing market, outlining clinical usage pathways and stratified care settings within the preterm births and prom testing market.
  • Assessing demand-supply imbalances through DROT-based market dynamics in the preterm births and prom testing market, reflecting clinical urgency factors, obstetric risk profiling, and evolving diagnostic prioritization.
  • Projecting market size trajectory over the next decade in the preterm births and prom testing market, incorporating revenue expansion in US$ Mn, volume uptake in units, CAGR momentum, and year-on-year growth variability.
  • Evaluating demand intensity shifts and regional uptake patterns in the preterm births and prom testing market, with emphasis on hospital infrastructure readiness, prenatal screening penetration, and geographically uneven clinical access.
  • Analyzing pricing sensitivity across diagnostic workflows in the preterm births and prom testing market, alongside upstream reagent sourcing, logistics dependencies, and value chain efficiencies influencing cost structures.
  • Profiling competitive intensity, company-level market share distribution, and merger-acquisition activity shaping consolidation trends in the preterm births and prom testing market, driven by diagnostic innovation pipelines.
  • Reviewing regulatory frameworks, product validation norms, and innovation cycles in the preterm births and prom testing market, alongside evolving sales and distribution channel strategies across clinical networks.
  • Examining parent diagnostic testing ecosystem linkages and country-level forecast scenarios in the preterm births and prom testing market, highlighting long-range strategic planning implications for healthcare systems.

- Frequently Asked Questions -

What are the major factors driving expansion in the preterm births and PROM testing market?

The market is primarily driven by rising awareness of early pregnancy risk detection, increasing demand for timely rupture-of-membrane assessment, and broader adoption of advanced diagnostic tools in maternal care pathways. Expanding clinical emphasis on preventive obstetric management and improved screening protocols further strengthens utilization across healthcare systems and specialized diagnostic settings.

Which key performance indicators are typically evaluated in this market landscape?

Key metrics include diagnostic accuracy indicators such as sensitivity and specificity, testing volumes across clinical workflows, and turnaround time for laboratory and point-of-care assessments. Additional performance indicators cover adoption rates of rupture-of-membrane testing solutions, clinical decision impact, and reduction in unnecessary interventions driven by improved early risk stratification tools.

What emerging shifts are influencing adoption patterns in this market?

Emerging trends highlight a shift toward rapid point-of-care testing, integration of digital diagnostic platforms, and increased preference for non-invasive screening approaches. There is also growing emphasis on personalized risk assessment in obstetric care, alongside the incorporation of biomarker-based technologies that enhance early identification of membrane rupture and preterm birth risks.

How is competition structured within the preterm births and PROM testing market?

Competitive dynamics are shaped by continuous product innovation, expanding portfolios of diagnostic assays, and strategic collaborations between diagnostic developers and clinical laboratories. Market participants focus on enhancing assay reliability, reducing processing complexity, and securing regulatory alignment. Consolidation activities and differentiation through rapid testing solutions further intensify competition across the value chain.

What segmentation-based insights are most relevant for understanding market behavior?

Segment-level insights indicate stronger traction for point-of-care testing formats compared to centralized laboratory workflows, driven by demand for faster clinical decisions. End-user adoption is expanding across hospitals, maternity clinics, and diagnostic centers, while biomarker-based assays are gaining preference due to improved reliability in assessing membrane rupture and preterm birth risks.

How is the market scope defined in terms of technologies and applications?

The market encompasses diagnostic solutions designed to detect preterm birth risk indicators and premature rupture of membranes through biochemical, immunoassay, and point-of-care technologies. It includes laboratory-based testing kits, rapid diagnostic devices, and integrated screening platforms used within maternal care pathways to support early clinical decision-making and risk stratification.

What are the primary strategic applications of these diagnostic solutions?

Strategic use cases span clinical pathway optimization, early risk detection programs, and improved resource allocation within maternal healthcare services. The market also supports evidence-based decision-making for obstetric management, enabling healthcare providers to reduce complications, enhance diagnostic efficiency, and streamline patient triage processes across diverse care settings.

What is the long-term outlook for developments in this market?

Future perspective for the market indicates sustained expansion driven by continued advancements in rapid diagnostics, stronger integration of biomarker-based technologies, and broader emphasis on preventive maternal care. Increasing reliance on early detection systems and workflow automation is expected to reshape clinical practice, improving overall outcomes and diagnostic efficiency over time.